Literature DB >> 1352058

Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

I K Wright1, M Heaton, N Upton, C A Marsden.   

Abstract

The aim of this study was to use the elevated X-maze to compare acute and chronic treatments of a 5-HT1A partial agonist, ipsapirone, a 5-HT2 antagonist, ritanserin, and a 5-HT3 antagonist, ondansetron, with those of established anxiolytic (diazepam) and anxiogenic (idazoxan) compounds. Acute diazepam (5 mg/kg IP) produced a significant increase in the percentage open:total entries and time and time spent in the end of the open arms (anxiolytic profile) on the elevated X-maze. Chronic treatment with diazepam (5 mg/kg IP twice daily for 14 days) still produced an anxiolytic profile which was not apparent 24 h after cessation of chronic treatment (withdrawal). In contrast, idazoxan given both acutely (0.25 mg/kg IP) and chronically (0.8 mg/kg/h at a flow rate of 5.5 microliters/h for 14 days, via osmotic minipumps) resulted in a significant decrease in the percentage open:total entries and time and time spent in the end of the open arms (anxiogenic profile). Acute administration of ipsapirone had no effect on any of the behavioural parameters at doses of 0.01 and 1 mg/kg IP, while 0.1 mg/kg IP produced a significant anxiogenic profile. Chronic treatment with ipsapirone (0.01, 0.1 and 1 mg/kg IP twice daily for 14 days) had no significant effect on rat behaviour on the X-maze but 24 h after ending treatment, ipsapirone at the highest dose used (1 mg/kg) produced a significant anxiogenic profile which was absent when the animals were tested 7 days after cessation of treatment. Ritanserin (0.05 and 0.25 mg/kg IP) had no effect acutely on any of the parameters measured but chronic treatment (0.25 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic effect which was still present 24 h but not 7 days after cessation of treatment. Acute ondansetron (0.01, 0.1 and 1 mg/kg IP) had no effect while chronic ondansetron (0.01 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic profile which was not a result of handling during the chronic dosing schedule, an effect was not measureable 24 h after treatment ended. The results demonstrate that the X-maze can detect anxiolytic activity in non-benzodiazepine drugs, as ritanserin and ondansetron showed anxiolytic profiles but only after chronic treatment. In contrast, the X-maze failed to detect any anxiolytic activity with the 5-HT1A partial agonist ipsapirone after either acute or chronic treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352058     DOI: 10.1007/bf02245168

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

1.  5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue.

Authors:  J M Barnes; N M Barnes; B Costall; R J Naylor; M B Tyers
Journal:  Nature       Date:  1989-04-27       Impact factor: 49.962

2.  Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test.

Authors:  B Söderpalm; S Hjorth; J A Engel
Journal:  Pharmacol Biochem Behav       Date:  1989-01       Impact factor: 3.533

Review 3.  Serotonin and anxiety revisited.

Authors:  R S Kahn; H M van Praag; S Wetzler; G M Asnis; G Barr
Journal:  Biol Psychiatry       Date:  1988-01-15       Impact factor: 13.382

4.  The effect of ketotifen in rodent models of anxiety and on the behavioural consequences of withdrawing from treatment with drugs of abuse.

Authors:  B Costall; M E Kelly; E S Onaivi; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

5.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function.

Authors:  J C Garratt; F Crespi; R Mason; C A Marsden
Journal:  Eur J Pharmacol       Date:  1991-01-25       Impact factor: 4.432

7.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

8.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

9.  L-5-hydroxytryptophan in the treatment of anxiety disorders.

Authors:  R S Kahn; H G Westenberg
Journal:  J Affect Disord       Date:  1985 Mar-Apr       Impact factor: 4.839

10.  Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat.

Authors:  S Pellow; A L Johnston; S E File
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

View more
  11 in total

1.  Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze.

Authors:  Antonio Pedro de Mello Cruz; Gilson Pinheiro; Sérgio Henrique Alves; Graziela Ferreira; Marília Mendes; Letícia Faria; Carlos Eduardo Macedo; Vitor Motta; J Landeira-Fernandez
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 2.  5HT drugs in animal models of anxiety.

Authors:  S L Handley; J W McBlane
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 3.  5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Authors:  J E Barrett; K E Vanover
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Noradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats.

Authors:  Carl D Smith; Christopher C Piasecki; Marcus Weera; Joshua Olszewicz; Joseph S Lonstein
Journal:  Behav Neurosci       Date:  2013-06-24       Impact factor: 1.912

5.  Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

Authors:  D J Dooley; I Klamt
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Variation in vasopressin receptor (Avpr1a) expression creates diversity in behaviors related to monogamy in prairie voles.

Authors:  Catherine E Barrett; Alaine C Keebaugh; Todd H Ahern; Caroline E Bass; Ernest F Terwilliger; Larry J Young
Journal:  Horm Behav       Date:  2013-01-28       Impact factor: 3.587

7.  Effects of two stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT.

Authors:  J W McBlane; S L Handley
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

8.  Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.

Authors:  R J Rodgers; J C Cole; J M Tredwell
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

9.  Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

Authors:  J K Shepherd; S S Grewal; A Fletcher; D J Bill; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

10.  Behavioral and cognitive changes after early postnatal lesions of the rat mediodorsal thalamus.

Authors:  Zakaria Ouhaz; Saadia Ba-M'hamed; Anna S Mitchell; Abdeslem Elidrissi; Mohamed Bennis
Journal:  Behav Brain Res       Date:  2015-06-12       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.